ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1074

Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Abstract Number: 1075

Impact of Immunosuppression on the Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Abstract Number: 1076

Rituximab-Associated Hypogammaglobulinemia in Patients with Rheumatic Diseases: A Multicenter Retrospective Observational Study
Abstract Number: 1077

Anti-drug Antibodies Formation During Tapering and Stopping of Methotrexate in Rheumatoid Arthritis Patients with Longstanding Use of Adalimumab
Abstract Number: 1078

Outcomes of COVID-19 Infection in Hospitalized Autoimmune Patients and Transplant Patients on Immunosuppression
Abstract Number: 1079

Identification of Immune Checkpoint Inhibitor-Induced Myositis Patients Using Electronic Health Records Is Most Successful When Employing Multiple Data Elements
Abstract Number: 1080

Prevalence and Incidence of Paradoxical Side-effects of TNF-α Inhibitors: A Cross-sectional Study
Abstract Number: 1081

Clinical Consequences of Infliximab Immunogenicity and the Impact of Proactive Therapeutic Drug Monitoring: Secondary Analyses of a Randomised Clinical Trial
Abstract Number: 1082

Reducing No-shows and Late Cancellations at an Academic Medical Center Subspecialty Clinic
Abstract Number: 1083

A Patient-Centered Approach to Increase Herpes Zoster Vaccination in Patients on Janus Kinase Inhibitors: A Fellowship Quality Improvement Initiative
Abstract Number: 1084

Identifying and Addressing Disparities in Health Literacy in Patients with Rheumatic Diseases Through Point of Care Distribution of Patient Education Materials
Abstract Number: 1085

Utilizing a Maintenance of Certification (MOC) Part 4 Quality Improvement Project to Improve Data Completeness in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Abstract Number: 1086

Increase Shingrix Vaccination Rate in Patients on JAK Inhibitors: A Quality Improvement Project at the Rheumatology Practice of an Urban Institution
Abstract Number: 1087

Characterizing Herpes Zoster Vaccination Patterns in Rheumatoid Arthritis Patients in a Tertiary Care Clinic: A Quality Improvement Approach
Abstract Number: 1088

Improving JIA Outcomes Assessments in a Large Pediatric Rheumatology Practice: A Fellow Quality Improvement Project

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].